Patents by Inventor Samuel Kaye

Samuel Kaye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240309019
    Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Application
    Filed: December 6, 2023
    Publication date: September 19, 2024
    Inventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
  • Patent number: 12060347
    Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 13, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
  • Patent number: 12037324
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: July 16, 2024
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
  • Patent number: 11932658
    Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and Ri, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: March 19, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
  • Publication number: 20230045357
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 9, 2023
    Applicants: Université de Montréal, Bristol-Myers Squibb Company
    Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
  • Patent number: 11407733
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 9, 2022
    Assignees: Bristol-Myers Squibb Company
    Inventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
  • Publication number: 20210188877
    Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Application
    Filed: January 6, 2021
    Publication date: June 24, 2021
    Inventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
  • Publication number: 20210163465
    Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 3, 2021
    Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
  • Patent number: 10730868
    Abstract: Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: August 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qinghong Fu, Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
  • Publication number: 20190315774
    Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Application
    Filed: July 13, 2017
    Publication date: October 17, 2019
    Inventors: XIAOJUN Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
  • Publication number: 20190300520
    Abstract: Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Application
    Filed: July 13, 2017
    Publication date: October 3, 2019
    Inventors: Qinghong Fu, Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
  • Publication number: 20190292176
    Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
    Type: Application
    Filed: July 13, 2017
    Publication date: September 26, 2019
    Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
  • Publication number: 20190202808
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Application
    Filed: June 28, 2017
    Publication date: July 4, 2019
    Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
  • Patent number: 4022585
    Abstract: A method for sealing and protecting the surface of advanced composite materials against moisture and other contaminants. Advanced composite materials, which comprise high strength fibers such as graphite or boron fibers in a resin matrix such as epoxy or polyimide resins, suffer a performance loss when subjected to moisture. In high vacuum environments, such as in many outer space applications, resin binder outgassing may cause contamination of the overall device. Significant dimensional changes occur when these composite structures are used in environments with widely varying humidity levels. The disclosed method of preventing such degradation basically comprises the steps of undercoating the surface with a metal coating, fluxing the undercoat, forming a layer of molten metal on the undercoat then solidifying the metal topcoating. A seal coating substantially impervious to water and highly resistant to dimensional changes and corrosion results.
    Type: Grant
    Filed: April 21, 1975
    Date of Patent: May 10, 1977
    Assignee: General Dynamics Corporation
    Inventor: Samuel Kaye